JP7650480B2 - ヒト条件的不死化細胞を用いた血液脳関門モデルおよびその製造方法 - Google Patents
ヒト条件的不死化細胞を用いた血液脳関門モデルおよびその製造方法 Download PDFInfo
- Publication number
- JP7650480B2 JP7650480B2 JP2020065670A JP2020065670A JP7650480B2 JP 7650480 B2 JP7650480 B2 JP 7650480B2 JP 2020065670 A JP2020065670 A JP 2020065670A JP 2020065670 A JP2020065670 A JP 2020065670A JP 7650480 B2 JP7650480 B2 JP 7650480B2
- Authority
- JP
- Japan
- Prior art keywords
- culture
- conditionally immortalized
- medium
- human
- differentiation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000008499 blood brain barrier function Effects 0.000 title claims description 115
- 210000001218 blood-brain barrier Anatomy 0.000 title claims description 114
- 238000004519 manufacturing process Methods 0.000 title claims description 22
- 210000003668 pericyte Anatomy 0.000 claims description 166
- 239000002609 medium Substances 0.000 claims description 131
- 210000001130 astrocyte Anatomy 0.000 claims description 127
- 210000004556 brain Anatomy 0.000 claims description 127
- 230000004069 differentiation Effects 0.000 claims description 124
- 210000004925 microvascular endothelial cell Anatomy 0.000 claims description 108
- 238000000034 method Methods 0.000 claims description 49
- 239000010410 layer Substances 0.000 claims description 35
- 239000001963 growth medium Substances 0.000 claims description 29
- 239000000758 substrate Substances 0.000 claims description 25
- 238000004113 cell culture Methods 0.000 claims description 24
- 238000010899 nucleation Methods 0.000 claims description 22
- 238000012258 culturing Methods 0.000 claims description 19
- 210000002966 serum Anatomy 0.000 claims description 13
- 239000002356 single layer Substances 0.000 claims description 13
- 239000003102 growth factor Substances 0.000 claims description 11
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 4
- 210000002744 extracellular matrix Anatomy 0.000 claims description 4
- 210000003061 neural cell Anatomy 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 description 124
- 238000004710 electron pair approximation Methods 0.000 description 29
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 21
- 230000006870 function Effects 0.000 description 20
- 230000014509 gene expression Effects 0.000 description 20
- 230000035699 permeability Effects 0.000 description 20
- 238000003501 co-culture Methods 0.000 description 19
- 101001017818 Homo sapiens ATP-dependent translocase ABCB1 Proteins 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 18
- 239000012528 membrane Substances 0.000 description 16
- 239000003814 drug Substances 0.000 description 15
- 229940079593 drug Drugs 0.000 description 13
- 108020004999 messenger RNA Proteins 0.000 description 13
- 238000000338 in vitro Methods 0.000 description 12
- 230000008569 process Effects 0.000 description 11
- 238000003753 real-time PCR Methods 0.000 description 11
- 102100022595 Broad substrate specificity ATP-binding cassette transporter ABCG2 Human genes 0.000 description 10
- 101000823298 Homo sapiens Broad substrate specificity ATP-binding cassette transporter ABCG2 Proteins 0.000 description 10
- 239000003242 anti bacterial agent Substances 0.000 description 10
- 210000003169 central nervous system Anatomy 0.000 description 10
- 238000003365 immunocytochemistry Methods 0.000 description 10
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 8
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 8
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 8
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 239000012091 fetal bovine serum Substances 0.000 description 8
- 229940116978 human epidermal growth factor Drugs 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- 108010078791 Carrier Proteins Proteins 0.000 description 7
- 229940088710 antibiotic agent Drugs 0.000 description 7
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 7
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 7
- DLBFLQKQABVKGT-UHFFFAOYSA-L lucifer yellow dye Chemical compound [Li+].[Li+].[O-]S(=O)(=O)C1=CC(C(N(C(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N DLBFLQKQABVKGT-UHFFFAOYSA-L 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- CXNPLSGKWMLZPZ-GIFSMMMISA-N (2r,3r,6s)-3-[[(3s)-3-amino-5-[carbamimidoyl(methyl)amino]pentanoyl]amino]-6-(4-amino-2-oxopyrimidin-1-yl)-3,6-dihydro-2h-pyran-2-carboxylic acid Chemical compound O1[C@@H](C(O)=O)[C@H](NC(=O)C[C@@H](N)CCN(C)C(N)=N)C=C[C@H]1N1C(=O)N=C(N)C=C1 CXNPLSGKWMLZPZ-GIFSMMMISA-N 0.000 description 6
- 102000015735 Beta-catenin Human genes 0.000 description 6
- 108060000903 Beta-catenin Proteins 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- CXNPLSGKWMLZPZ-UHFFFAOYSA-N blasticidin-S Natural products O1C(C(O)=O)C(NC(=O)CC(N)CCN(C)C(N)=N)C=CC1N1C(=O)N=C(N)C=C1 CXNPLSGKWMLZPZ-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000002889 endothelial cell Anatomy 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000004888 barrier function Effects 0.000 description 5
- 239000007640 basal medium Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 210000004692 intercellular junction Anatomy 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000032258 transport Effects 0.000 description 5
- 102100037362 Fibronectin Human genes 0.000 description 4
- 108010067306 Fibronectins Proteins 0.000 description 4
- 101000655352 Homo sapiens Telomerase reverse transcriptase Proteins 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- 102000008674 Major facilitator superfamily domains Human genes 0.000 description 4
- 108050000477 Major facilitator superfamily domains Proteins 0.000 description 4
- 239000012580 N-2 Supplement Substances 0.000 description 4
- 108091006296 SLC2A1 Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000002457 bidirectional effect Effects 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000002490 cerebral effect Effects 0.000 description 4
- 230000003511 endothelial effect Effects 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- -1 serum Substances 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- 102100028163 ATP-binding cassette sub-family C member 4 Human genes 0.000 description 3
- 101710149917 ATP-binding cassette sub-family C member 4 Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 3
- 102000003746 Insulin Receptor Human genes 0.000 description 3
- 108010001127 Insulin Receptor Proteins 0.000 description 3
- 229930182816 L-glutamine Natural products 0.000 description 3
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 3
- 102000052339 Monocarboxylate transporter 8 Human genes 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 238000002123 RNA extraction Methods 0.000 description 3
- 108091006599 SLC16A2 Proteins 0.000 description 3
- 108010033576 Transferrin Receptors Proteins 0.000 description 3
- 102000007238 Transferrin Receptors Human genes 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 210000002867 adherens junction Anatomy 0.000 description 3
- CJGYSWNGNKCJSB-YVLZZHOMSA-N bucladesine Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](OC(=O)CCC)[C@@H]2N1C(N=CN=C2NC(=O)CCC)=C2N=C1 CJGYSWNGNKCJSB-YVLZZHOMSA-N 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 238000009509 drug development Methods 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000009343 monoculture Methods 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 229920000139 polyethylene terephthalate Polymers 0.000 description 3
- 239000005020 polyethylene terephthalate Substances 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 108010047303 von Willebrand Factor Proteins 0.000 description 3
- 102100036537 von Willebrand factor Human genes 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000004266 Collagen Type IV Human genes 0.000 description 2
- 108010042086 Collagen Type IV Proteins 0.000 description 2
- 108010015340 Low Density Lipoprotein Receptor-Related Protein-1 Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 2
- 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102000008790 VE-cadherin Human genes 0.000 description 2
- 108010054176 apotransferrin Proteins 0.000 description 2
- 229930189065 blasticidin Natural products 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 108010018828 cadherin 5 Proteins 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 102000044162 human IGF1 Human genes 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- TUFFYSFVSYUHPA-UHFFFAOYSA-M rhodamine 123 Chemical compound [Cl-].COC(=O)C1=CC=CC=C1C1=C(C=CC(N)=C2)C2=[O+]C2=C1C=CC(N)=C2 TUFFYSFVSYUHPA-UHFFFAOYSA-M 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 108091035539 telomere Proteins 0.000 description 2
- 102000055501 telomere Human genes 0.000 description 2
- 210000003411 telomere Anatomy 0.000 description 2
- 210000001578 tight junction Anatomy 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- 229960001134 von willebrand factor Drugs 0.000 description 2
- 230000003313 weakening effect Effects 0.000 description 2
- 239000002676 xenobiotic agent Substances 0.000 description 2
- CBCKQZAAMUWICA-UHFFFAOYSA-N 1,4-phenylenediamine Chemical compound NC1=CC=C(N)C=C1 CBCKQZAAMUWICA-UHFFFAOYSA-N 0.000 description 1
- KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000004057 Claudin-5 Human genes 0.000 description 1
- 108090000582 Claudin-5 Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 1
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003693 Hedgehog Proteins Human genes 0.000 description 1
- 108090000031 Hedgehog Proteins Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical group [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000003940 Occludin Human genes 0.000 description 1
- 108090000304 Occludin Proteins 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 208000016012 Phenotypic abnormality Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000000591 Tight Junction Proteins Human genes 0.000 description 1
- 108010002321 Tight Junction Proteins Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102000013814 Wnt Human genes 0.000 description 1
- 108050003627 Wnt Proteins 0.000 description 1
- 102000044820 Zonula Occludens-1 Human genes 0.000 description 1
- 108700007340 Zonula Occludens-1 Proteins 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000002247 constant time method Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 1
- 229960001936 indinavir Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 229910052749 magnesium Chemical group 0.000 description 1
- 239000011777 magnesium Chemical group 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000025569 negative regulation of astrocyte differentiation Effects 0.000 description 1
- 229940000041 nervous system drug Drugs 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 238000012762 unpaired Student’s t-test Methods 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020065670A JP7650480B2 (ja) | 2020-04-01 | 2020-04-01 | ヒト条件的不死化細胞を用いた血液脳関門モデルおよびその製造方法 |
| JP2024191126A JP2025017371A (ja) | 2020-04-01 | 2024-10-30 | ヒト条件的不死化細胞を用いた血液脳関門モデルおよびその製造方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020065670A JP7650480B2 (ja) | 2020-04-01 | 2020-04-01 | ヒト条件的不死化細胞を用いた血液脳関門モデルおよびその製造方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024191126A Division JP2025017371A (ja) | 2020-04-01 | 2024-10-30 | ヒト条件的不死化細胞を用いた血液脳関門モデルおよびその製造方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021159015A JP2021159015A (ja) | 2021-10-11 |
| JP7650480B2 true JP7650480B2 (ja) | 2025-03-25 |
Family
ID=78001522
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020065670A Active JP7650480B2 (ja) | 2020-04-01 | 2020-04-01 | ヒト条件的不死化細胞を用いた血液脳関門モデルおよびその製造方法 |
| JP2024191126A Pending JP2025017371A (ja) | 2020-04-01 | 2024-10-30 | ヒト条件的不死化細胞を用いた血液脳関門モデルおよびその製造方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024191126A Pending JP2025017371A (ja) | 2020-04-01 | 2024-10-30 | ヒト条件的不死化細胞を用いた血液脳関門モデルおよびその製造方法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (2) | JP7650480B2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115354016A (zh) * | 2022-09-13 | 2022-11-18 | 中山大学 | 一种体外血脑屏障模型的构建方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017179375A1 (ja) | 2016-04-15 | 2017-10-19 | 国立大学法人山口大学 | 血液脳関門インヴィトロモデルおよび血液脳関門インヴィトロモデルの作製方法 |
-
2020
- 2020-04-01 JP JP2020065670A patent/JP7650480B2/ja active Active
-
2024
- 2024-10-30 JP JP2024191126A patent/JP2025017371A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017179375A1 (ja) | 2016-04-15 | 2017-10-19 | 国立大学法人山口大学 | 血液脳関門インヴィトロモデルおよび血液脳関門インヴィトロモデルの作製方法 |
Non-Patent Citations (1)
| Title |
|---|
| 薬学部 降幡知巳教授がプレスリリース『可逆的不死化細胞によるヒト血液脳関門モデルの開発に成功』，東京薬科大学[online]，2019年10月23日，URL: https://www.toyaku.ac.jp/pharmacy/newstopics/2019/1023_3135.html，[retrieved on 2024.03.06] |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025017371A (ja) | 2025-02-05 |
| JP2021159015A (ja) | 2021-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lv et al. | Construction of tumor organoids and their application to cancer research and therapy | |
| US12517112B2 (en) | Immune cell organoid co-cultures | |
| EP2970896B1 (en) | Engineered liver tissues, arrays thereof, and methods of making the same | |
| EP2582790B1 (en) | Human blood-brain endothelial cells derived from pluripotent stem cells and blood-brain barrier model thereof | |
| US20190185818A1 (en) | Novel chicken egg-based metastasis model for cancer | |
| JP2010500878A (ja) | ポリマー膜を用いた幹細胞とフィーダー細胞の共培養方法 | |
| JP2015511482A (ja) | ３ｄインビトロ二相性軟骨構造物 | |
| TW201233800A (en) | Lung tissue model | |
| JP2017532008A (ja) | 三次元複合細胞凝集体モデル並びにその製造方法及び応用 | |
| SG175425A1 (en) | Lung tissue model | |
| Pocock et al. | Maturation of human cardiac organoids enables complex disease modeling and drug discovery | |
| Liu et al. | Efficient enrichment of hepatic cancer stem-like cells from a primary rat HCC model via a density gradient centrifugation-centered method | |
| US20250041346A1 (en) | Thymic epithelial stem cells | |
| JP2025017371A (ja) | ヒト条件的不死化細胞を用いた血液脳関門モデルおよびその製造方法 | |
| Rassomakhina et al. | Tumor organoids: the era of personalized medicine | |
| Chiabotto et al. | Narrative review of in vitro experimental models of hepatic fibrogenesis | |
| KR101916902B1 (ko) | Cd71 표면 표지인자를 마커로 하여 인간 배아줄기세포로부터 응수축성 심근세포를 제조하는 방법 | |
| US20180044640A1 (en) | Contractile cellular construct for cell culture | |
| KR102927837B1 (ko) | 형질전환된 인간 간성상세포주 및 이의 용도 | |
| Nasehi et al. | 3D geometry orchestrates the transcriptional landscape of metastatic neuroblastoma cells in a multicellular in vitro bone model | |
| WO2002103033A1 (fr) | Procede pour detecter et isoler des cellules hepatiques indifferenciees au moyen de dlk | |
| Štefániková et al. | Insight into the pathogenesis of interstitial lung diseases and near-to-native lung fibrosis models | |
| JP6486619B2 (ja) | 薬物評価用細胞及び薬物評価方法 | |
| Farhangnia et al. | Identification of placenta-specific protein 1 (PLAC-1) expression on human PC-3 cell line-derived prostate cancer stem cells compared to the tumor parental cells | |
| JP2019198252A (ja) | 近位尿細管上皮細胞株及びその使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A80 | Written request to apply exceptions to lack of novelty of invention |
Free format text: JAPANESE INTERMEDIATE CODE: A80 Effective date: 20200408 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200710 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230320 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20240228 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240312 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240502 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240624 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20240731 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240806 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241030 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20241112 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250218 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250305 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7650480 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |